Neointimal Coverage After Implantation of Biolimus Eluting Stent With Biodegradable Polymer: Optical Coherence Tomographic Assessment According to the Treatment of Dyslipidemia and Hypertension and the Types of Implanted Drug-eluting Stents

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 120 participants.

Also called NCT01502904

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 120 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01502904
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01502904. Randomized; single masking; primary purpose treatment. Start 2010-07 (registry gives no type); primary completion 2015-05 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Neointimal Coverage After Implantation of Biolimus Eluting Stent With Biodegradable Polymer: Optical Coherence Tomographic Assessment According to the Treatment of Dyslipidemia and Hypertension and the Types of Implanted Drug-eluting Stents
Condition
Stable Angina or Acute Coronary Syndrome Considered for Percutaneous Coronary Intervention With Dyslipidemia or Hypertension
Intervention (Device)
Sirolimus-eluting stent
Intervention (Device)
Biolimus-eluting stents
Intervention (Drug)
pravastatin 20mg/day after DES implantation
Intervention (Drug)
pitavastatin 2mg/day after DES implantation
Intervention (Drug)
Non-ARB /day after DES implantation
Intervention (Drug)
Eposartan 600mg/day after DES implantation
Lead sponsor
Yonsei University (class: other)

Record details

Record id
cardio:ct-nct01502904
Content hash
33fabcd8dc61fe42ee61698594e030db95063c9949426f47c97aa48c65df903e